New drug combo targets Hard-to-Treat endometrial cancer
Disease control
Ongoing
This study tests two drugs, alpelisib and fulvestrant, in 51 people with advanced or returning endometrioid endometrial cancer that has a specific gene change (PIK3CA mutation) and is estrogen-receptor positive. The goal is to see if the combination can shrink tumors. Treatment c…
Phase: PHASE2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC